Relationship between the paraoxonase (PON1) L55M and Q192R polymorphisms and obesity in a Mexican population: A pilot study

Genes and Nutrition

Volumn 6, Issue 4, 2011, Pages 361-368

  Martínez Salazar, Maria Fernanda ^a   Almenares López, Damianys ^a   García Jiménez, Sara ^a   Sánchez Alemán, Miguel Angel ^b   Juantorena Ugás, Alina ^a   Ríos, Camilo ^c   Monroy Noyola, Antonio ^a  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Human; Obesity; Paraoxonase; Polymorphism; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICAN; OBESITY; PARAOXONASE 1 GENE; PILOT STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; WORKER;

EID: 81755162823     PISSN: 15558932     EISSN: 18653499     Source Type: Journal    
DOI: 10.1007/s12263-011-0215-0     Document Type: Article

References (39)

1. S Adkins KN Gan M Mody, et al. 1993 Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes Am J Hum Genet 52 598 608 7916578 1:CAS:528:DyaK2cXhvVKjsr8%3D (Pubitemid 23311330)
2. M Audikovszky G Pados I Seres, et al. 2007 Orlistat increases serum paraoxonase activity in obese patients Nutr Metab Cardiovasc Dis 17 268 273 17134960 10.1016/j.numecd.2006.03.004 1:CAS:528:DC%2BD1cXlslGruw%3D%3D (Pubitemid 46551690)
3. M Aviram S Billecke R Sorenson, et al. 1998 Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R Artherioscler Thromb Vasc Biol 18 1617 1624 10.1161/01.ATV.18.10.1617 1:CAS:528:DyaK1cXmvFGhs7w%3D (Pubitemid 28465415)
4. S Barquera I Campos-Nonato L Hernandez-Barrera, et al. 2009 Obesity, central adiposity in Mexican adults: results from the Mexican national health, nutrition survey 2006 Salud Publica Mex 51 Suppl 4 S595 S603 20464235
5. MC Blatter Garin RW James P Dussoix, et al. 1997 Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes J Clin Invest 99 62 66 10.1172/JCI119134 (Pubitemid 27058295)
6. L Christiansen L Bathum H Frederiksen, et al. 2004 Paraoxonase1 polymorphisms and survival Eur J Hum Genet 12 843 847 15241482 10.1038/sj.ejhg.5201235 1:CAS:528:DC%2BD2cXns1ektrg%3D (Pubitemid 39406069)
7. LG Costa WF Li RJ Richter DM Shih, et al. 1999 The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism Chem Biol Interact 119-120 429 438 10421480 10.1016/S0009-2797(99)00055-1 (Pubitemid 29278580)
8. LG Costa A Vitalone T Cole, et al. 2005 Modulation of paraoxonase (PON1) activity Biochem Pharm 69 541 550 15670573 10.1016/j.bcp.2004.08.027 1:CAS:528:DC%2BD2MXmvFKgtA%3D%3D
9. HW Eckerson CM Wyte BN La Du 1983 The human serum paraoxonase/ arylesterase polymorphism Am J Hum Genet 35 1126 1138 6316781 1:CAS:528:DyaL2cXjt1Kktg%3D%3D (Pubitemid 14201166)
10. E Falaschetti A Hingorani A Jones, et al. 2010 Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children Eur Heart J 31 3063 3072 20972265 10.1093/eurheartj/ehq355 1:CAS:528:DC%2BC3cXhsF2rs7nM
11. G Ferretti T Baccheti C Moroni, et al. 2005 Paraoxonase activity in high density lipoproteins: a comparison between healthy and obese females J Clin Endocrinol Metab 90 1728 1733 15613429 10.1210/jc.2004-0486 1:CAS:528: DC%2BD2MXisVOhtbw%3D (Pubitemid 40464045)
12. G Ferretti T Bacchetti S Masciangelo, et al. 2010 HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects Obesity 6 1079 1084 10.1038/oby.2009.338
13. CE Furlong RJ Richter SL Seidel, et al. 1988 Role of genetic polimorphism of human plasma paraoxonase/arylesterase in hydrolisis of the insecticide metabolites chlorpyrofos oxon and paraoxon Am J Hum Genet 43 230 238 2458038 1:CAS:528:DyaL1MXjsFOrsg%3D%3D
14. R Gamboa J Zamora JM Rodríguez-Pérez, et al. 2006 Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile Exp Mol Pathol 80 85 90 15993880 1:CAS:528: DC%2BD2MXhtlGisbnE (Pubitemid 41828231)
15. KN Gan A Smolen HW Eckerson, et al. 1991 Purification of human serum paraoxonase/arylesterase Drug Metab Dispos 19 100 106 1673382 1:CAS:528:DyaK3MXnslGhtg%3D%3D
16. JP Habicht 1974 Estandarización de métodos epidemiológicos cuantitativos sobre el terreno (standardization of anthropometric methods in the field) PAHO Bull 76 375 384 1:STN:280: DyaE2c3ptVWnsA%3D%3D
17. RA Hegele JH Brunt PW Connelly 1995 A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate Arterioscler Thromb Vasc Biol 15 89 95 7749820 10.1161/01.ATV.15.1.89 1:STN:280:DyaK2M3mvV2nsA%3D%3D
18. HB Hubert M Feinleib PM McNamara, et al. 1983 Obesity as an independent risk factor for cardiovascular disease: a 26 years follow up participants in the Framinham heart study Circulation 72 53 60
19. R Humbert DA Adler CM Disteche, et al. 1993 The molecular basis of the human serum paraoxonase activity polymorphism Nat Genet 3 73 76 8098250 10.1038/ng0193-73 1:CAS:528:DyaK3sXpsFCitQ%3D%3D (Pubitemid 23063292)
20. K Kazuhiko K Nakane Y Sano, et al. 2009 Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women J Clin Biochem Nutr 45 329 334 10.3164/jcbn.09-26
21. P Koncsos I Seres M Harangi, et al. 2010 Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels Pediatr Res 67 309 313 19915520 10.1203/PDR.0b013e3181c9fb66 1:CAS:528:DC%2BC3cXitVSqu7k%3D
22. A Kuniyasu S Hayashi H Nakayama 2002 Adipocytes recognize and degrade oxidized low density lipoprotein through CD36 Biochem Biophys Res Commun 295 319 323 12150950 10.1016/S0006-291X(02)00666-6 1:CAS:528:DC%2BD38XltFersLg%3D (Pubitemid 34785836)
23. I Leviev N Franco RW James 1997 Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism Arterioscler Thromb Vasc Biol 17 2935 2939 9409279 10.1161/01.ATV.17.11.2935 1:CAS:528:DyaK1cXisV2hsQ%3D%3D (Pubitemid 28016045)
24. B Mackness P Durrington M Mackness 1999 Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation Lancet 353 468 469 9989726 10.1016/S0140-6736(98)05105-8 1:CAS:528:DyaK1MXht12qsLw%3D (Pubitemid 29067347)
25. MI Mackness S Arrol PN Durrington 1991 Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein FEBS Lett 286 152 154 1650712 10.1016/0014-5793(91)80962-3 1:CAS:528:DyaK3MXltFWgu7Y%3D
26. MI Mackness PN Durrington 1995 HDL: its enzymes and its potential to influence lipid peroxidation Atherosclerosis 115 243 253 7661883 10.1016/0021-9150(94)05524-M 1:CAS:528:DyaK2MXls12jtrc%3D
27. MI Mackness S Arrol B Mackness, et al. 1997 Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation Lancet 349 851 852 9121268 10.1016/S0140-6736(05)61755-2 1:CAS:528:DyaK2sXisVagtbs%3D (Pubitemid 27129220)
28. R Marsella R Vari M D'Archivio, et al. 2006 Oxidised LDL modulate adipogenesis in 3T-L1 preadipocytes by affecting the balance between cell proliferation and differentiation FEBS Lett 580 2421 2429 10.1016/j.febslet. 2006.03.068 (Pubitemid 44389367)
29. J Marsillach B Mackness M Mackness, et al. 2008 Immunohistochemical analysis of paraoxonases-1,2 and 3 expression in normal mouse tissues Free Radic Biol Med 45 146 157 18440321 10.1016/j.freeradbiomed.2008.03.023 1:CAS:528:DC%2BD1cXntlSnu7g%3D
30. National Institutes of Health (2000) The practical guide identification, evaluation, and treatment of overweight and obesity in adults. http://www.nhlbi.nih.gov/guidelines/obesity/prctgd-c.pdf
31. M Odawara Y Tachi K Yamashita, et al. 1997 Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus J Clin Endocrinol Metab 82 2257 2260 9215303 10.1210/jc.82.7.2257 1:CAS:528:DyaK2sXksVeru70%3D (Pubitemid 27287594)
32. AE Rojas-García MJ Solís-Heredia B Piña- Guzmán, et al. 2005 Genetic polymorphisms and activity of PON1 in a Mexican population Toxicol Appl Pharmacol 205 282 289 15922013 10.1016/j.taap.2004.10.015 (Pubitemid 40726303)
33. M Rosenblat L Gaidukov O Khersonsky, et al. 2006 The catalytic histidine dyad of HDL-associated serum paraoxonase 1 (PON1) is essential for PON1-mediated inhibition of LDL oxidation and for stimulation of macrophage cholesterol efflux J Biol Chem 281 7657 7665 16407304 10.1074/jbc.M512595200 1:CAS:528:DC%2BD28Xit1ygur4%3D (Pubitemid 43847536)
34. E Saruhan A Olgun K Oztürk, et al. 2007 Age-related paraoxonase activity changes in Turkish population Ann NY Acad Sci 1100 218 222 17460182 10.1196/annals.1395.022 1:CAS:528:DC%2BD2sXlslOitro%3D (Pubitemid 47092656)
35. I Seres G Paragh E Deschene, et al. 2004 Study of factors influencing the decreased HDL associated PON1 activity with aging Exp Gerontol 39 59 66 14724065 10.1016/j.exger.2003.08.001 1:CAS:528:DC%2BD2cXjsFWitA%3D%3D (Pubitemid 38068260)
36. TIA Sorensen SM Echwald J-C Holm 1996 Leptin in obesity Br Med J 313 953 954 1:STN:280:DyaK2s%2FkslCrsw%3D%3D (Pubitemid 26385516)
37. S Tabur AN Torun T Sabuncu 2010 Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation Eur J Endocrinol 162 535 541 20022940 10.1530/EJE-09-0732 1:CAS:528:DC%2BC3cXjtFahsL4%3D
38. HK Vincent AG Taylor 2006 Biomarkers and potencial mechanisms of obesity-induced oxidant stress in humans Int J Obes 30 400 418 10.1038/sj.ijo.0803177 1:CAS:528:DC%2BD28Xhsl2htb0%3D
39. World Health Organization 1995 Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee World Health Organ Tech Rep Ser 854 1 452